ÂÜÀòÂÒÂ×

Mayumi Holly has a solid background in microbiology, with experience in various research roles in both academic and industry settings. Mayumi has worked on projects related to transcription factors in Shigella, adenovirus replication, and inflammasome activation in response to bacterial infection. Mayumi currently holds the position of Principal Scientist at Tune Therapeutics, where Mayumi leads the Molecular Analysis and Product Characterization team within Product Development. Prior to this, Mayumi has worked at Umoja Biopharma and Bristol Myers Squibb in analytical development and CMC roles. Mayumi obtained their Ph.D. in Microbiology from the University of Washington and their Bachelor of Science from Washington State University.